AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00928083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 800mg API capsules
Description: OZ439 800mg (4x200 API capsules)
Study NCT00928083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 1200mg API capsules
Description: OZ439 1200mg (6x200mg API capsules)
Study NCT00928083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00928083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 200mg aqueous dispersion
Study NCT03503448 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Osteotomy between the maxillary central incisors
Description: Surgically Assisted Rapid Maxillary Expansion with osteotomy between the central incisors.
Study NCT03503448 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Osteotomy between the maxillary lateral incisors and canines
Description: Surgically Assisted Rapid Maxillary Expansion with bilateral osteotomy between the lateral incisors and canines
Study NCT01830569 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The EBMeDS system
Description: The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.~The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group.
Study NCT01830569 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evidence Linker
Description: The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
Study NCT01830569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence Linker
Description: The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
Study NCT02924480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystectomy
Study NCT02924480 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Cystectomy
Study NCT02924480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive lidocaine infusion during surgery
Study NCT02924480 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive saline infusion during surgery
Study NCT05478226 — intervention group
Intervention type: OTHER
Intervention: drugs or BPA
Description: PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
Study NCT02116049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Disclosure Intervention
Description: The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
Study NCT02116049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control Case Management
Description: Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
Study NCT01365429 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XPS™ with Steen Solution™
Description: The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
Study NCT02388763 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Stenfilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized
Study NCT02388763 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Narafilcon A contact lenses
Description: Contact lenses worn during Period 1 or 2, as randomized
Study NCT01052090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHN121
Description: a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
Study NCT03876561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor prehabilitation
Description: The systematic pelvic floor prehabilitation will start 4 weeks before stoma closure and will include 1 session per week before stoma closure and 1 session per week during 6 weeks following stoma closure. The prehabilitation will be performed according to a predefined protocol based on a biofeedback strategy.
Study NCT03451201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: High Intensity Interval Exercise Training in cycle ergometer, exercising at 80% of maximal capacity during one minute alternated with exercise at 50% of maximal capacity during 4 minutes intervals, for a total of 30 minutes. Three times a week for 8 weeks
Study NCT03451201 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Continuous Exercise Training
Description: Moderate Continuous Exercise Training 3 times a week for 8 weeks at 50% of maximal capacity
Study NCT03451201 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-exercise
Description: Conventional care for sedentary Type 1 Diabetes Controls. No intervention.
Study NCT02170688 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isovue 370
Description: All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
Study NCT02170688 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight calculation
Study NCT02079532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera]
Description: 1 g was given by intravenous infusion on Days 1 and 15
Study NCT01471366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Frozen capsule
Description: Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
Study NCT01471366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule with food
Description: Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
Study NCT01471366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule without food
Description: Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
Study NCT01471366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Capsule with milk
Description: Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
Study NCT04641559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized nutrition group
Description: A digital environment which combines biological information, personal habits and preference to provide nutritional recommendations. This digital environment is composed by the follow softwares:1. The recommender system: software that combine the behavioral and biological information about the volunteer and generates personalized nutritional recommendations; 2. The ALDI microsite: A microsite that retrieves the personalized recommendations for the volunteer from the recommender system. The ALDI microsite matches food categories with products of the ALDI catalogue. As a result, the volunteer receives a list of products classified under different food categories that are recommended for him/her. Next to each food category, the number of servings recommended (weekly or daily) is also shown.~The ALDI microsite is a tool only to elaborate a shopping list through personalized recommendations. Therefore, volunteers can choose to buy their food shopping list at wherever store other from ALDI.
Study NCT04641559 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized Plan group
Description: Participants will use the same software described in for the Personalized nutrition group together with a behavioral change program designed to increase the adherence to the recommendations provided by the ALDI microsite by promoting a proper attitude by means of a series of personalized, goal-orientated, friendly, achievable actions delivered periodically to the volunteer. The behavioral change program will be fed with the results of behavior questionnaires. The personalized messages will be delivered through the ALDI microsite. These personalized messages will be available only for those subjects engaged in the Personalized Plan group.
Study NCT04641559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The participants in the control group will not have personalized recommendations. These participants will have access to a restricted version of the ALDI microsite where the list of recommended products correspond to categories that are general recommendations according to Mediterranean diet.
Study NCT01117610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (one of medication)
Description: patients in Group C will receive none of medication preoperatively and intraoperatively
Study NCT01117610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (epidural injection)
Description: patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
Study NCT01210001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching BI 10773 low dose
Study NCT01210001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 10773
Description: BI 10773 tablets once daily
Study NCT01210001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets matching BI 10773 high dose
Study NCT01210001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching BI 10773 high dose
Study NCT04287426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium 0.6 mg/kg
Description: Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
Study NCT04287426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil 2 µg/kg
Description: Rocuronium 0.6 mg/kg is compared to patients with 2 µg/kg remifentanil
Study NCT00825227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Armodafinil 150 mg/day
Description: * 150 mg/day armodafinil~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents
Study NCT00825227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,
Description: * placebo~* concurrent with one cycle of taxane chemotherapy alone or in combination with other agents~* patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents
Study NCT02494765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: I-gel TM
Description: Airway management with I-gel
Study NCT02494765 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambu AuraOnce (AO)
Description: Airway management with Ambu AuraOnce (AO)
Study NCT02333370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Description: LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
Study NCT02333370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 25mg
Study NCT02333370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Description: 20 mg
Study NCT02333370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg
Study NCT02333370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin
Study NCT00577668 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan, Velcade, Thalidomide, Dexamethasone
Description: To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
Study NCT02162069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE certified transcatheter ( aortic valve replacement)
Description: Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
Study NCT03064022 — intervention group
Intervention type: OTHER
Intervention: Growth
Description: Some preterm infants grow at higher rates than others
Study NCT03066453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobi Inhalant Product
Description: inhaled tobramycin 300 mg twice per day
Study NCT03066453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebcin
Description: 10 to 12 mg/kg/day in 1 injection for adults and 10 to 15 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
Study NCT02253979 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard double lumen tube
Description: Endotracheal left side double lumen tube
Study NCT02253979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VivaSight double lumen tube
Description: VivaSight double lumen endotracheal intubation
Study NCT00584311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI and Ultrasound
Description: MRI and US of the joint
Study NCT02272764 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Administered orally in a crossover design
Study NCT02272764 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 5461
Description: Administered sublingually in a crossover design
Study NCT04008979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin - lipid complex
Study NCT04008979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin - lipid complex
Study NCT03437148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innocor®
Description: Inert gas rebreathing device: Innocor® (Innovision, Odense, Denmark)
Study NCT03437148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physioflow®
Description: Bioimpedance cardiograph: Physioflow® (Manatec, France)
Study NCT03127137 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Experimental Group 1 triamcinolone and lidocaine
Description: Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
Study NCT03127137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Experimental Group 2 triamcinolone and saline
Description: Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
Study NCT03709862 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Whole Genome Sequencing
Description: Residual DNA from clinical samples will be utilised for whole genome sequencing of Treponema pallidum the causative agent of syphilis
Study NCT00684671 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix
Description: Intramuscular injection, single dose in left deltoid.
Study NCT00684671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Engerix-B
Description: Intramuscular injection, single dose in left deltoid.
Study NCT00684671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: Intramuscular injection, single dose in right deltoid.
Study NCT00684671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HBVAXPRO
Description: Intramuscular injection, single dose in the left deltoid.
Study NCT00684671 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaqta
Description: Intramuscular injection, single dose in right deltoid.
Study NCT00113425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V-Beam laser, Candela Corp., 595 nm wavelength
Description: Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
Study NCT06266962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Atropine drops
Description: Patients administered 1% Atropine drops twice a day for a week before the cataract surgery.
Study NCT06266962 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epinephrine
Description: Patients underwent the instillation of epinephrine into the anterior chamber at the beginning of the cataract surgery.
Study NCT03392298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colla corii asini
Description: 15g Colla corii asini granule, once daily for 4 weeks
Study NCT04182971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit
Description: Phase 1 is 227g of orange fruit, Phase 2 is 230g of apple fruit
Study NCT04182971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fruit juice
Description: Phase 1 is 250g of orange juice, Phase 2 is 235g of apple juice
Study NCT04182971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit juice plus fiber
Description: Phase 1 is 157g of orange juice + 100g of orange pomace fiber (39% pomace by weight), Phase 2 is 129g of apple juice + 106g of apple pomace fiber (45% pomace by weight)
Study NCT00438828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
Study NCT02393040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRP/Saline
Description: PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.~Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head.
Study NCT04607720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: artificial-EUS-FNA
Description: The ultrasound endoscopists manually determined the region of interest (ROI) according to CH-EUS, and punctured 2 needles in the tumor area with a 22G needle, and each needle moved 15-20 times back and forth in the lesion. After puncture, insert the needle core, rinse the needle with 0.1ml sterile saline, and further apply air flushing to ensure that each tissue is sent to the slide.
Study NCT04607720 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AI-EUS-FNA
Description: In the AI-assisted diagnosis system, the assisted targeting EUS-FNA unit is applied, and the ultrasound endoscopist selects the region of interest (ROI) according to the thermogram to perform targeted EUS-FNA puncture(2 needles in the same way).